The basic helix-loop-helix (bHLH) protein E2-2 is known to play a role in quiescence of endothelial cells (ECs). However, how the activity of E2-2 is controlled in the cells is still unclear. In this study, we identified FAM96B as an interaction partner of E2-2. FAM96B interfered with E2-2-mediated effects on luciferase reporter activities. Furthermore, the suppression of VEGFR2 promoter activity by E2-2 was rescued by the expression of FAM96B in a dose-dependent manner. 
Introduction
The basic-helix-loop-helix (bHLH) protein E2-2, alternatively termed ITF2, TCF4, SEF2, and SEF2-1B, was originally identified as a transcription factor that binds to the µE5 and κE2 motifs in the immunoglobulin heavy and light chain enhancers, respectively (1) . Together with E12/47 and HEB, E2-2 belongs to the E protein family. E proteins are widely expressed in tissues and bind to consensus DNA sequences containing (G/A)CAXXTG(G/A) as either homodimers or heterodimers with other HLH family molecules (2, 3) . The E protein family is known to regulate lymphocyte development (4), neural differentiation (5) , and myogenesis (6) . Recently, we and another group demonstrated that E proteins also regulate blood vessel formation (7) (8) (9) .
The activity of E proteins is known to be controlled via their interaction with other HLH proteins (10) , coactivators (11, 12) , or corepressors (13) as well as via their own phosphorylation (14) . The Id family, which lacks the basic region important for DNA binding activity, associates with E proteins to inhibit their DNA binding activity (10) . The coactivators CBP and p300 interact with E proteins via their AD1 domain to potentiate their transcriptional activity (11, 12) , although the ETO family blocks the transcriptional activity of E proteins via its direct interaction (13) .
Angiogenesis, the formation of new blood vessels, is crucial for vascular development and homeostasis. Aberrant vascularization leads us to a number of diseases including atherosclerosis, tumorigenicity, and retinopathy. Angiogenesis occurs by sprouting of new vessels from preexisting ones or by intussusceptive microvascular growth. Thus, angiogenesis is essential during embryonic development as well as in adulthood. In general, vascular formation is quiet in adulthood although angiogenesis involved in wound healing, inflammation, ischemia, and the female reproductive cycle has been observed (15) . Angiogenesis is divided into two phases: the activation phase and the resolution phase. The angiogenic switch depends on a finely tuned balance between stimulators (VEGF, FGF-2, angiopoietins, hypoxia, and so on) and inhibitors (angiostatin, endostatin, interferon-α, and so on). During the activation phase, proliferation of endothelial cells (ECs), increase of vascular permeability, and degradation of extracellular matrix components can be observed. Consequently, ECs make new capillary sprouts. During the resolution phase, the proliferation and migration of ECs stops, whereafter the basement membrane is reconstituted and the vessels mature (16) .
In our recent studies, E2-2 as well as E2A inhibited the activity of the VEGFR2 promoter to inhibit the activity of endothelium in vivo and in vitro. In contrast, Id1 and SCL/TAL1, both of which possess the HLH domains, relieved E2-2-mediated inhibition of VEGFR2 promoter activity because of heterodimer formation with E2-2 (7, 8) .
However, partner(s) other than HLH-containing proteins can still regulate the activity of E2-2.
To gain more insight into the molecular mechanisms by which E2-2 suppresses the activity of endothelium, we surveyed its interaction partner(s) and identified FAM96B, alternatively named CGI-128. However, its function has yet to be identified. In this study, we explored the regulatory role of FAM96B on the function of E2-2. In addition, we examined its function in EC activation. We found that FAM96B promoted decrease of E2-2 protein to rescue E2-2-mediated repression of VEGFR2 promoter activity. Consequently, FAM96B concomitantly enhanced EC migration, proliferation and tube formation.
Material and Methods

Plasmids and adenoviruses
The cDNA for human FAM96B was cloned by RT-PCR and sequenced to be verified prior to use. FAM96B(42-121) and FAM96B∆ (42-121) were generated by Pfx DNA polymerase (Invitrogen) using human FAM96B as the template. Subsequently, each DNA was ligated into either Flag-pDEF3 or Myc-pDEF3 (17) . Myc-E2-2 and Flag-E2-2 have been previously described (8) . MCKpfos-luc was generously provided by Dr. M.
Sigvardsson (18) , and pGL2b-VEGFR2-luc (-166bp/+267bp) by Dr. C. C. W. Hughes (19) . Adenovirus expressing Myc-FAM96B was generated using the pAdTrack-CMV vector (20). After pAdTrack-CMV-Myc-FAM96B was recombined with pAdEasy-1 (20), the resulting plasmid was transfected into 293T cells, and the adenoviruses were amplified. LacZ-and constitutively active activin receptor-like kinase 6 (ALK6ca)/HA-expressing adenoviruses are previously described (8) .
Cell culture COS7 cells, NIH3T3 cells, and mouse embryonic endothelial cells (MEECs) (21) were maintained in Dulbecco's modified Eagle's media (DMEM, Sigma) containing 10% fetal calf serum (FCS, Gibco), 1X MEM nonessential amino acids (NEAA, Invitrogen), and 100 U/mL penicillin/streptomycin. Calf pulmonary artery epithelial cells (CPAEs) (22) were cultured in DMEM with 10% FCS, 20 mM HEPES, and 100 U/mL penicillin/streptomycin. Primary human umbilical vein endothelial cells (HUVECs) were cultured in EBM (TAKARA) supplemented with 2% FCS. MEECs and HUVECs were grown on 0.1% gelatin-coated dishes.
Adenoviral infections
Adenoviruses were incubated in DMEM containing polybrene (80 µg/mL) for 2 h and added to the dishes. Two hours after infection, the cells were washed and allowed to recover for 24 h prior to the experiments.
Immunoprecipitation and Western blotting
To detect interactions among proteins, plasmids were transfected into COS7 cells 
Transcriptional reporter assay
CPAEs were seeded at 5 x 10 4 cells/well in 12-well plates one day prior to the transfection. The cells were transfected using Lipofectamine TM and Plus TM Reagent. After 40 h of transfection, the lysates were prepared and the luciferase activity was measured using a luciferase assay system (Promega). The results were corrected for β-galactosidase 
Network formation assay
HUVECs (2 x 10 4 cells/well in an 8-well Lab-Tek ® chamber; ThermoFisher) infected with adenoviruses were seeded on growth factor-reduced Matrigel (BD Biosciences, San Jose, CA). Images were captured 6 h and 12 h after ECs were seeded (8) . The total area of tube-like structures formed by HUVECs in each well was measured using Image J from NIH.
Cell proliferation
Proliferation was measured by the incorporation of 
RNA isolation and RT-PCR
Total RNA was isolated using the RNeasy kit (QIAGEN, Valencia, CA). Reverse transcription was carried out by using a First-Strand cDNA Synthesis Kit (TAKARA).
PCR was performed using Ex Taq polymerase (TAKARA) as directed by the manufacturer. Primer sets used are shown in Supplementary Table I . As seen in Fig. 1c, FAM96B mRNA was augmented upon BMP signaling in a similar fashion to Id1. On the other hand, the expression of E2-2 mRNA was not changed upon the ALK6 activation (Suppl. Fig. 1 ). Furthermore, Id1 mRNA, was induced in endothelial cells by VEGF as expected, whereas VEGF did not enhance the expression of FAM96B transcript (Suppl. Fig. 2 ). It remains veiled why the stimulation of BMP, but not that of VEGF, accelerated the expression of FAM96B transcript in endothelial cells. We will need further exploration in the future experiments.
Results
Identification of FAM96B as an interaction partner of E2-2-When
Inhibitory effect of FAM96B on E2-2-mediated promoter activity -The
MCKpfos-luc reporter construct consisting of four E-box elements has been used to investigate the function of E proteins (18) . Our previous studies reported that Id1 and SCL/TAL1, which are interaction partners of E2-2, could counteract E2-2-mediated MCKpfos-luc reporter activity (7, 8) . To examine the possibility that FAM96B affects the MCKpfos-luc reporter activity induced by E2-2, we transfected a different amount of FAM96B expression vector into the CPAE cells with or without E2-2. FAM96B
inhibited the E2-2-mediated activity of this reporter in a dose-dependent manner ( Figure   2a ) To further confirm that FAM96B influences the transcriptional activity of E2-2, we employed the pGL2b-VEGFR2-luc (-166bp/+267bp) luciferase reporter construct, which E2-2 negatively controls (7, 8) . Consistent with the result shown in Fig. 2a, FAM96B dose-dependently released the E2-2-mediated inhibition of pGL2b-VEGFR2-luc (-166bp/+267bp) luciferase activity (Fig. 2b) . These results demonstrated the possibility that FAM96B interferes with the transcriptional regulation of E2-2.
Activation of EC by FAM96B-E2-2 has been reported to hamper the expression of VEGFR2 in ECs to keep ECs quiescent, whereas Id1 and SCL/TAL1 rescue the E2-2-mediated suppression of ECs (7, 8) . Migration, proliferation, survival, and differentiation in ECs are considerably altered during the process of EC activation. To investigate the effect of FAM96B on EC migration, we infected HUVECs with either GFP-or FAM96B-expressing adenoviruses prior to seeding the ECs on a fibronectin-coated filter (Fig. 3a) . We then counted the number of ECs under the chamber.
As seen in Figure 3b , FAM96B potentiated the EC migration. Again, the overexpression of FAM96B in HUVECs decreased the E2-2 protein (Fig. 3a) . We also tested whether FAM96B affected cell proliferation and network formation in ECs after ECs were infected with either GFP-or FAM96B-expressing adenoviruses. Overexpression of FAM96B in ECs potentiated both the cell growth (Fig. 3c ) and the formation of cord-like structures ( Fig. 3d and 3e) . Thus, these observations indicate that in contrast to E2-2, FAM96B has the ability to keep ECs active.
Effect of FAM96B on the expression of E2-2-Because ectopic FAM96B seems to
influence the expression of E2-2 protein in COS7 cells (Fig. 1a) and HUVECs (Fig. 3a) , we further investigated whether the expression of E2-2 protein is attenuated by the ectopic expression of FAM96B. When Myc-FAM96B was overexpressed with Flag-E2-2 in COS7 cells, the expression of Flag-tagged E2-2 was diminished with the increasing expression of Myc-FAM96B (Fig. 4a) , and vice versa (Fig. 4b) . Thus, the decrease of E2-2 expression mediated by FAM96B was not dependent on the tags. Furthermore, the ectopic expression of FAM96B decreased the endogenous E2-2 protein in NIH3T3 cells (Fig. 4c) . Since E12/47 belongs to the E protein family, we also tested if FAM96B affected the expression of the E47 protein. Expectedly, the expression of E47 protein was also decreased by FAM96B to the same extent as that of E2-2. On the other hand, the expression of neither Smad2 (Fig. 4d ) nor c-myc (Suppl. Fig. 3 ) was altered by FAM96B.
Therefore, this finding strongly suggests that FAM96B is able to specifically affect the protein expression of the E protein family. (29) (30) (31) . In our previous studies, E2-2 kept ECs quiescent, whereas the HLH proteins Id1 and SCL/TAL1 were capable of overcoming the inhibitory action of E2-2 on EC functions (7, 8) . In the present study, FAM96B, which is not a member of the HLH Since a number of proteins in cells can be degraded through either the proteasomal or the lysosomal pathways (32), we tried to investigate whether FAM96B
Exploration of the functional domain in FAM96B-
can also decrease the expression of the E2-2 protein via these pathways. However, the decrease of E2-2 expression mediated by FAM96B was not rescued by inhibitors specific for either proteasomes or lysosomes (Suppl. Fig. 4 and 5) . As another possibility, we checked the transcript of E2-2 with or without FAM96B in either the absence or the presence of actinomycin D. However, the transcript of E2-2 was not altered by FAM96B
(data not shown). These results indicate the possibility that FAM96B can activate a certain protease(s) that targets E2-2. Because we currently do not know the exact mechanism by which FAM96B can diminish the expression of the E2-2 protein, several possibilities still need to be explored. Furthermore, it is interesting to analyze that FAM96B can be regulated at a transcriptional and/or a translational level by itself.
In a previous study, we found that E2-2 interfered with EC activation while its interaction partners Id1 and SCL/TAL1 overcame the function of E2-2 and activated ECs (7, 8) . Besides, FAM96B was found as one of BMP-inducing genes like Id1 in our present study. Therefore, we assumed that FAM96B could also potentiate the function of ECs.
Indeed, we were convinced that FAM96B can promote EC activation. Importantly, the expression of endogenous E2-2 protein was diminished by FAM96B, demonstrating that FAM96B restricts the expression of E2-2 protein to control E2-2-mediated cellular responses in ECs. Our hypothesis can be further supported by the evidence that FAM96B
could rescue the E2-2-mediated suppression of the VEGFR2 promoter. Thus, it is high possibility that the protein expression of VEGFR2 is influenced by FAM96B. This possibility will be tested in our further investigation. Since E2-2 is ubiquitously expressed in cells, it will be interesting to know if FAM96B regulates the function of E2-2 via the control of E2-2 expression in cell types other than ECs. Our preliminary study indicated that FAM96B could not compete with Id1 for the interaction with E2-2 despite the fact that both Id1 and FAM96B can associate with E2-2. Therefore, the function of E2-2 might be fine-tuned at different steps within cells via the regulation of its protein expression, its DNA binding ability, and so forth.
In conclusion, we discovered a novel mechanism by which FAM96B impairs the expression of E2-2 protein in ECs to potentiate EC activation. The identification of compounds that bolster E2-2 activity via the activation of FAM96B in ECs may provide an exciting opportunity to modulate tumor angiogenesis for therapeutic intervention. 
